The newest Mendelian randomization study showed that, for PCSK9-mAbs, LDL-C lowering per standard deviation decrease in PCSK9 expression indicated a modest T2DM risk reduction. This evidence concerns the gene PCSK9 and type 2 diabetes mellitus.